This clinical trial is trying to determine if adding a drug with excellent brain penetration to your current therapy will control your brain metastases for longer and prolong the amount of time until another brain metastases occurs. This trial is for patients who have HER2-Positive MBC. It is a single-arm trial, meaning that all patients on the trial will receive the trial drug, Tucatinib, in addition to their standard of care treatment.
The trial is investigating the question of whether adding Tucatinib to your current therapy will help prolong the amount of time until another brain metastases occurs compared to historical data.
Read more about the BRIDGET clinical trial here.
Watch the video below to hear to Dr. Sarah Sammons, a breast medical oncologist at Dana-Farber Cancer Institute at Harvard Medical School, discuss the BRIDGET Trial.